We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs. The composite incidence of recurrent TIA and IS, acute myocardial infarction (AMI), and cardiovascular (CV) death was 4.21 and 19.2%, respectively at one and five years after the index event, an estimate unexpectedly lower than reported in the general population. Patients tended to replicate the first clinical manifestation (hazard ratio, HR: 2.41 and 4.41 for recurrent TIA and IS, respectively); additional factors for recurrent TIA were previous TIA (HR: 3.40) and microvascular disturbances (HR: 2.30); for recurrent IS arterial hypertension (HR: 4.24) and IS occurrence after MPN diagnosis (HR: 4.47). CV mortality was predicted by age over 60 years (HR: 3.98), an index IS (HR: 3.61), and the occurrence of index events after MPN diagnosis (HR: 2.62). Cytoreductive therapy was a strong protective factor (HR: 0.24). The rate of major bleeding was similar to the general population (0.90 per 100 patient-years). In conclusion, the long-term clinical outcome after TIA and IS in MPN appears even more favorable than in the general population, suggesting an advantageous benefit-risk profile of antithrombotic and cytoreductive treatment.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms / V. De Stefano, A. Carobbio, V. Di Lazzaro, P. Guglielmelli, A. Iurlo, M.C. Finazzi, E. Rumi, F. Cervantes, E.M. Elli, M.L. Randi, M. Griesshammer, F. Palandri, M. Bonifacio, J.-. Hernandez-Boluda, R. Cacciola, P. Miroslava, G. Carli, E. Beggiato, M.H. Ellis, C. Musolino, G. Gaidano, D. Rapezzi, A. Tieghi, F. Lunghi, G.G. Loscocco, D. Cattaneo, A. Cortelezzi, S. Betti, E. Rossi, G. Finazzi, B. Censori, M. Cazzola, M. Bellini, E. Arellano-Rodrigo, I. Bertozzi, P. Sadjadian, N. Vianelli, L. Scaffidi, M. Gomez, E. Cacciola, A.M. Vannucchi, T. Barbui. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - 8:3(2018 Feb), pp. 25.1-25.12.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms

M.C. Finazzi;D. Cattaneo;A. Cortelezzi;
2018

Abstract

We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs. The composite incidence of recurrent TIA and IS, acute myocardial infarction (AMI), and cardiovascular (CV) death was 4.21 and 19.2%, respectively at one and five years after the index event, an estimate unexpectedly lower than reported in the general population. Patients tended to replicate the first clinical manifestation (hazard ratio, HR: 2.41 and 4.41 for recurrent TIA and IS, respectively); additional factors for recurrent TIA were previous TIA (HR: 3.40) and microvascular disturbances (HR: 2.30); for recurrent IS arterial hypertension (HR: 4.24) and IS occurrence after MPN diagnosis (HR: 4.47). CV mortality was predicted by age over 60 years (HR: 3.98), an index IS (HR: 3.61), and the occurrence of index events after MPN diagnosis (HR: 2.62). Cytoreductive therapy was a strong protective factor (HR: 0.24). The rate of major bleeding was similar to the general population (0.90 per 100 patient-years). In conclusion, the long-term clinical outcome after TIA and IS in MPN appears even more favorable than in the general population, suggesting an advantageous benefit-risk profile of antithrombotic and cytoreductive treatment.
Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Survival Rate; Brain Ischemia; Hematologic Neoplasms; Myeloproliferative Disorders; Stroke
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
s41408-018-0048-9.pdf

accesso aperto

Descrizione: Open Access
Tipologia: Publisher's version/PDF
Dimensione 626.88 kB
Formato Adobe PDF
626.88 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/725020
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 16
social impact